Literature DB >> 6208220

Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigens by enzyme-linked immunosorbent assay.

J M Middeldorp, J Jongsma, A ter Haar, J Schirm, T H The.   

Abstract

A sensitive and reproducible enzyme-linked immunosorbent assay (ELISA) is described for the detection of immunoglobulin M and antibodies with specifity for human cytomegalovirus (CMV) early (CMV-EA) and late (CMV-LA) antigens. The emphasis is on the production of high-quality CMV antigens, CMV-EA and CMV-LA separately, and conditions for their application in the ELISA. The induction of CMV-EA and -LA in infected cell extracts was studied in detail by using human sera with defined antibody specificity for CMV-EA and CMV-LA. This resulted in the development of a simple whole cell extraction procedure that provided a high yield of CMV antigens with reproducible antigen quality. The antigens were specific for the detection of anti-CMV antibodies. The influence of autoantibodies on the determination of CMV-specific antibodies was investigated. Parallel analysis of 322 human sera by indirect immunofluorescence and ELISA showed a high correlation between both assays (r = 0.9674 for CMV-EA and 0.9362 for CMV-LA). Antibody titers determined by ELISA were equal to (for CMV-EA) or slightly higher (for CMV-LA) that those determined by immunofluorescence but significantly higher (20- to 5,120-fold) than those determined by complement fixation. From 191 sera positive by ELISA (titer greater than or equal to 40) 4 (2.1%) were negative by immunofluorescence (titer less than 40), and from 61 ELISA-positive sera 12 (19.6%) were negative (titer less than 8) when tested by complement fixation. Consequently, ELISA for CMV may prove to be more reliable for the selection of CMV-seronegative blood donors than these other methods. The use of high-quality antigens allows more economic handling of large-scale serum determinations. Possibilities for further automation are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208220      PMCID: PMC271427          DOI: 10.1128/jcm.20.4.763-771.1984

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  Rapid detection of IgG and IgM antibodies for cytomegalovirus by the enzyme linked immunosorbent assay (ELISA).

Authors:  R Cappel; F de Cuyper; J de Braekeleer
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

2.  Synthesis of proteins and glycoproteins in cells infected with human cytomegalovirus.

Authors:  M F Stinski
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

3.  Antibodies against cytomegalovirus-induced early antigens (CMV-EA) in immunosuppressed renal-allograft recipients.

Authors:  T H The; H K Andersen; E S Spencer; G Klein
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

4.  Solid-phase enzyme immunoassay for immunoglobulin M antibodies to cytomegalovirus.

Authors:  H Schmitz; H W Doerr; D Kampa; A Vogt
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

5.  Improved glycine-extracted complement-fixing antigen for human cytomegalovirus.

Authors:  J D Kettering; N J Schmidt; E H Lennette
Journal:  J Clin Microbiol       Date:  1977-12       Impact factor: 5.948

6.  Demonstration of IgM cytomegalovirus-antibodies as an aid to early diagnosis in adults.

Authors:  M M Langenhuysen; T H The; H O Nieweg; J G Kapsenberg
Journal:  Clin Exp Immunol       Date:  1970-03       Impact factor: 4.330

7.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

8.  Antibody reactions to virus-specific early antigens (EA) in patients with cytomegalovirus (CMV) infection.

Authors:  T H The; G Klein; M M Langenhuysen
Journal:  Clin Exp Immunol       Date:  1974-01       Impact factor: 4.330

9.  Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections.

Authors:  S Stagno; D W Reynolds; A Tsiantos; D A Fuccillo; W Long; C A Alford
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

10.  Enzyme-immunoassays for antibodies in measles, cytomegalovirus infections and after rubella vaccination.

Authors:  A Voller; D E Bidwell
Journal:  Br J Exp Pathol       Date:  1976-04
View more
  25 in total

1.  Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection.

Authors:  J van Zanten; M van der Giessen; L H van der Voort; W J van Son; W van der Bij; T H The
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

2.  Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection.

Authors:  M Van der Giessen; A P van den Berg; W van der Bij; S Postma; W J van Son; T H The
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

3.  The influence of cytomegalovirus carrier status on lymphocyte subsets and natural immunity.

Authors:  J W Gratama; M Kardol; A M Naipal; J Slats; A Den Ouden; T Stijnen; J D'Amaro; T H The; J W Bruning
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

4.  Cytomegalovirus early and late membrane antigens detected by antibodies in human convalescent sera.

Authors:  J M Middeldorp; J Jongsma; T H The
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

5.  Detection of specific immunoglobulin M antibodies to cytomegalovirus by using monoclonal antibody to immunoglobulin M in an indirect immunofluorescence assay.

Authors:  M Zerbini; M Musiani; G Gentilomi; M La Placa
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

6.  Immunofluorescence for detection of antibodies against human cytomegalovirus-induced membrane antigens.

Authors:  J M Middeldorp; J Jongsma; T H The
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

7.  IgG subclass-specific antibodies to human cytomegalovirus (HCMV)-induced early antigens.

Authors:  A Hamann; H W Doerr
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

8.  Detection of antibody to cytomegalovirus-induced early antigens and comparison with four serologic assays and presence of viruria in blood donors.

Authors:  E B Lentz; N L Dock; C A McMahon; S R Fiesthumel; C B Arnold; H V Lamberson
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

9.  Selective impairment of T lymphocyte activation through the T cell receptor/CD3 complex after cytomegalovirus infection.

Authors:  M Timón; A Arnaiz-Villena; J Ruiz-Contreras; J T Ramos-Amador; A Pacheco; J R Regueiro
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

10.  An enzyme immunoassay for immunoglobulin M antibodies to Toxoplasma gondii which is not affected by rheumatoid factor or immunoglobulin G antibodies.

Authors:  T M Lin; M W Chin-See; S P Halbert; J M Joseph
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.